Massive Bio
AI clinical trial matching and enrollment platform for oncology. SYNERGY-AI extracts structured information from patient records including biomarker data and matches against a reported 19,000+ active oncology and hematology trials, with matches audited by certified oncology case managers before use. The platform includes physician and patient facing assistants and a trial enrollment orchestration layer (TrialRelay). Peer reviewed evidence is unusually strong for this category: a prospective evaluation in 3,804 metastatic cancer patients published in ESMO Real World Data and Digital Oncology reported matching four times faster than conventional methods using a neuro symbolic, multi agent architecture with an oncology specific knowledge graph. Reports 200,000+ onboarded patients and customers spanning pharma, CROs, and community oncology practices.
Capability Axes
The product is the matching engine: natural language understanding extracts structured data from medical records and a neuro symbolic, multi agent architecture over an oncology specific knowledge graph performs the trial matching. AI is the deliverable.
Human oversight is explicit and structural rather than implied: AI generated matches are audited and managed by certified oncology case managers before reaching the patient or physician, and a virtual tumor board program sits over the process. One of the clearest oversight disclosures in the index.
Rare peer reviewed prospective evidence for a matching product: a study in ESMO Real World Data and Digital Oncology prospectively evaluated the platform in 3,804 metastatic cancer patients in routine practice during 2024, reporting matching four times faster than conventional methods. Graded on the existence and design of the evidence; this index does not re verify the underlying results.
No public pricing. Contact the vendor. Revenue comes from pharma, CRO, and provider contracts; the patient facing matching application is free to patients.
Precisely bounded: oncology and hematology trial matching, spanning solid and hematological malignancies, adult and pediatric, delivered through community oncology practices and pharma and CRO partners. Explicit scope.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Pharma, CRO, and provider contracts; patient facing application is free to patients | — | — | Vendor Published |
Revenue comes from pharma, CRO, and provider organization contracts. The patient facing trial matching application is free to patients. No published rate card for the enterprise channel.